Introduction: Multifocal motor neuropathy (MMN) is a rare, treatable, immune-mediated neuropathy often associated with multifocal conduction block (CB). The hallmark electrodiagnostic feature is the presence of CB occurring at non-entrapment sites. However, MMN without CB has also been described and can be diagnosed, even in the absence of CB. Therefore, it is crucial to diagnose and identify MMN cases without CB, as it is a treatable disorder. Case presentation: We present a case with progressive symptoms of asymmetric distal upper and lower extremity weakness with no sensory deficits. Intravenous immunoglobulin (IVIG) therapy was initiated, as the patient fulfilled the criteria for probable MMN, despite the absence of CB. The patient’s symptoms demonstrated a relative plateau phase in response to IVIG. Although the patient lost follow-up visits, repeated electrodiagnostic study, conducted 11 years after initial presentation, revealed new CB in nerve segments that previously did not show any evidence of CB. Conclusion: This case emphasizes the importance of early diagnosis and respectively initiating early IVIG treatment in MMN, in order to maintain the clinical function. Underdiagnosis of clinically suspected MMN, based on absence of CB, will result in denial of treatment to potential IVIG responders.
Multifocal motor neuropathy, conduction block, intravenous immunoglobulin
Said R Beydoun has received grant research support from Alexion, Argenx, Daiichi Pharma, and Pfizer. He has served as an advisory board member for Grifols, MT Pharma and Sarepta, and is a speaker for Grifols. Leila Darki has nothing to disclose in relation to this article.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Compliance with Ethics: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions. Written informed consent was not obtained from the patient for publication of this case report due to loss of follow-up; no identifying information or images were used in the publication of this paper.
Leila Darki, Neuromuscular Division, Keck School of Medicine, University of Southern California, 1520 San Pablo St, Suite 3000, Los Angeles, CA 90033, US. E: Leila.email@example.com
This article is published under the Creative Commons Attribution Noncommercial License, which
permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
Share this Article
Related Content In Neuromuscular Diseases
LGMDR1 with Prominent Limb–Joint Contractures and Inflammatory Changes Misdiagnosed as Scleromyositis with a Novel CAPN3 Mutation: A Case Report
touchREVIEWS in Neurology. 2023;19(1): DOI: https://doi.org/10.17925/USN.2023.19.1.46
Highlights Limb–joint contractures may represent an important clinical clue of muscle dystrophies, as they limit the spectrum of the diagnosis assumptions. Limb–girdle muscular dystrophies phenotype can rarely be a clinical presentation of retractile myopathies, except for non-specific Achilles tendon tightness. Anti-PM/Scl antibody screening using line-blot assays and commercial antibody–panel testing is likely to detect false-positive antibodies. Dysferlinopathies, calpainopathy and facioscapulohumeral muscular dystrophy are the conditions most frequently confused […]
Hirayama Disease: Review on Pathophysiology, Clinical Features, Diagnosis and Treatment
touchREVIEWS in Neurology. 2022;18(2):109–16 DOI: https://doi.org/10.17925/USN.2022.18.2.109
Hirayama disease (HD) is a lower motor neurologic disorder that manifests in young males in their early 20s, manifesting with gradually progressive weakness and wasting of C7-T1 innervated muscles. Dynamic magnetic resonance imaging (MRI) clinches the diagnosis, and treatment is mainly supportive using a cervical brace, and in refractory cases, surgical. This review aims to […]
Treatment for Spinal Muscular Atrophy Using Onasemnogene Abeparvovec
touchREVIEWS in Neurology. 2022;18(2): 133-41 DOI: https://doi.org/10.17925/USN.2022.18.2.133
Background for molecular-based therapy for spinal muscular atrophy Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease and the most common cause of infant death worldwide, with an incidence of 1:10,000 live births and carrier frequency of 1:50.1 This disease, caused by degeneration of spinal and bulbar motor neurons, is characterized by progressive muscle […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!